GEN Exclusives

More »

GEN News Highlights

More »
Aug 2, 2013

Beckman Coulter Life Sciences Acquires ReaMetrix' Flow Cytometry Business

  • Beckman Coulter Life Sciences acquired the flow cytometry business of India’s ReaMetrix, in a deal that broadens the buyer’s tool and technology offerings to include reagents designed to simplify sample preparation and provide highly standardized combinations to its global laboratory customers. The acquisition price was undisclosed.

    “The simplification of customer workflows will be dramatic,” Mario Koksch, vp and general manager of the cytometry business unit of Beckman Coulter Life Sciences, said in a statement. “We’ll be able to offer customers an extended line of market-leading technology while expanding our reach within two key segments for flow cytometry—HIV monitoring and clinical research."

    ReaMetrix products are among the first dry, temperature-stable flow cytometry reagents CE-marked for in vitro diagnostic use in Europe. However, the diagnostic reagents are not currently available or cleared for use in the United States.

    ReaMetrix products include the Immedia system, an in vitro diagnostics platform designed to perform complex, high-sensitivity assays in clinical chemistry and biochemistry, immunology, clinical microbiology, and immunocytometry.

    Immedia spans multiple sample types, assay formats, and disciplines of diagnostic information, bringing into one system laser optics, optomechanical movements, microfluidics, high-sensitivity detection electronics, data processing, and unique dry and unitized assay reagents—such as the company’s room-temperature-stable, single-dose, multi-color antibody cocktails.

    Beckman Coulter is a unit of Danaher. Speaking with analysts on the second-quarter earnings conference call July 18, Danaher President and CEO H. Lawrence Culp said his company had closed on $300 million in Q2 acquisitions focused on life sciences and diagnostics as well as on its environmental business. “Given our healthy balance sheet, we have more than $8 billion of potential M&A capacity available through 2014 to expand and strengthen our strategic growth platforms,” Culp said, according to a transcript by Morningstar.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?